Venture Capitalist Opposes US Restrictions on Investment in China's Drug Industry
The U.S. government is currently debating whether to slow or block American biotech deals that could benefit China. This discussion intensified recently, with some legislators advocating for the addition of biotechnology to the COINS Act, which would allow federal scrutiny of various investment arrangements. However, venture capitalist Julie Grant believes such restrictions would be shortsighted, arguing they could hinder U.S. drug development and negatively impact patients.
The question of potential U.S. government intervention in American biotech deals benefiting China has gained significant attention in recent months. A proposal by some legislators seeks to include biotechnology under the COINS Act, which would enable the U.S. government to restrict investments in specific industries.
Such a move would introduce federal oversight to licensing agreements, equity investments, and other common arrangements within the biotech sector.
Venture capitalist Julie Grant has voiced her opposition to these proposed restrictions. She views such measures as a misguided attempt to reverse decades of growing interdependence between U.S. and Chinese industries.
Grant contends that even if American companies could reduce their reliance on Chinese research organizations and drug developers, doing so would ultimately impede U.S. drug development efforts and harm patients.
According to STAT News, Grant believes this approach would be shortsighted.
